Reproductive Health

The Medications Optimizing Maternal Safety (MOMS) program offers vital support to pregnant patients through community pharmacies.

Recent research reveals no link between menopause hormone therapy and dementia risk, urging further studies to clarify its effects on cognitive health.

A study determined that lifestyle factors and comorbidities were more likely to be associated with the onset of diabetes.

Recent research reveals no significant link between prenatal acetaminophen use and increased risks of autism or ADHD in children, challenging FDA claims.

Preeclampsia significantly raises the risk of chronic kidney disease (CKD) later in life, highlighting the need for targeted postpartum monitoring for affected women.

Gestational diabetes disrupts RNA splicing in the placenta, revealing potential targets for improving pregnancy outcomes.

The guidelines are believed to promote screening adherence by providing women with a more comfortable, accessible, and less stressful testing option.

Pharmacists play a vital role in preventing maternal and neonatal mortality by understanding pregnancy-specific medication needs and emergency care strategies.

The American Cancer Society updates cervical cancer screening guidelines, introducing self-collection options and new exit criteria to enhance accessibility and compliance.

Pharmacists Can Educate Patients About Symptoms of Menopause, Associated Chronic Conditions, and Management Options

Natural strategies and OTC options can help manage menopause symptoms, from hot flashes to mood changes, for a smoother transition.

Guselkumab and paltusotine received FDA approval, Kenvue announced the new Tylenol Precise Pain-Relieving Patch, and a new generic version of mifepristone received the green light from the FDA.

Elinzanetant Showed Smaller Reductions in Bone Mineral Density Than Placebo

The Annual Meeting Highlighted Emerging Research on Hormone Therapy, Brain and Heart Health, Disparities in Menopause Care, and the Expanding Role of Pharmacists

FDA Approval Introduces a First-in-Class Neurokinin Receptor Agonist Shown to Reduce Vasomotor Symptom Frequency and Improve Sleep Quality in Postmenopausal Women

How can a natural biological evolution with so many consequences get relatively little attention from research and practice?

Research highlights significant barriers to contraceptive use and reproductive health management for women with chronic kidney disease (CKD), urging improved nephrology care.

Two experts discuss sessions that covered perimenopause, premature ovarian insufficiency, GLP-1–based treatments, and the health needs of Indigenous and Hispanic women.

Research highlights the link between earlier menopause, cardiac function, and brain health, emphasizing the need for sex-specific dementia risk strategies.

Research highlights the impact of provider type on menopause treatment, revealing a need for standardized education to improve care quality for women.

The authors wrote that their findings show a necessary update following early data from the Women’s Health Initiative.

Further research is needed to better understand which characteristics may better predict who are more likely to benefit from estrogen-based menopausal hormonal therapy (MHT) for anxiety.

New clinical trial results suggest G-CSF as a promising alternative for managing hot flashes in menopausal women, without the risks of traditional therapies.

Research highlights the impact of sleep disturbances and vasomotor symptoms (VMS) on HRQoL in women transitioning to menopausal period, emphasizing the need for effective management.